Last reviewed · How we verify
NCT04622696
HydroMARK Post-market Clinical Follow-up Study
trial testing Ultrasound imaging in Breast Cancer in 730 participants. Completed in 7 August 2023.
7 August 2023
Quick facts
| Lead sponsor | Devicor Medical Products, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 730 |
| Start date | 16 February 2021 |
| Primary completion | 7 August 2023 |
| Estimated completion | 7 August 2023 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Ultrasound imaging
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Devicor Medical Products, Inc.
Who can join
18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the safety and performance of the HydroMARK Breast Biopsy Site Marker manufactured in the Devicor Medical Products, Inc. Tijuana facility.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04622696
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ultrasound imaging
Trials testing the same drug.
- NCT06809972 — Synovial Proliferation on Routine Ultrasound: Active or Inactive? · not yet recruiting
- NCT06625905 — Ultrasound Assessment of Myofascial Trigger Points · completed
- NCT06648577 — 3D Ultrasound Myocardial Mechanical Wave Measurements · recruiting
- NCT06675747 — Evaluation of the Effect of Occlusal Splint Use on Masticatory Muscles · completed
- NCT06514638 — Computational Mathematical Analysis in Vastus Medialis Between a MTrP and Non Painful Point · completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04622696 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Devicor Medical Products, Inc.
- Last refreshed: 5 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04622696.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing